Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA testing. In order to conserve the remaining reagent, a controlled process of batch testing was implemented. Therefore, you will likely see additional delays in receiving these supplemental test results.
Read about our plan to mitigate this on the Communications page by clicking this link: Communications
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...
This is the first update to the original CTS communication distributed on July 6th. As previously co...